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in participants with diabetes. METHODS: Caremark’s
pharmacy claims database was retrospectively analyzed
to identify participants ﬁlling a prescription for an 
anti-diabetic drug in plans with average participant cost-
sharing of <15% (LOW) or >30% (HIGH) in 2002. Ten
age/gender categories were used to match participants in
the HIGH and LOW study groups. All 2002 anti-diabetic
maintenance drug claims for study participants were 
analyzed. Compliance rates were calculated for each 
therapeutic class as the medication possession ratio. Two
sample t-Tests compared differences in compliance rates
between HIGH and LOW groups. RESULTS: A total 
of 125,963 individual diabetics were identiﬁed (47.7%
HIGH; 46% female; 89% >44yrs). Overall, the mean
medication compliance rates were consistently higher for
the diabetics with low participant cost-share. The mean
medication compliance rate for LOW was 1.00 (95% CI:
1.004, 1.008) and for HIGH was 0.90 (95% CI: 0.903,
0.907; p < .0001). The mean medication compliance rate
for females in LOW was 1.00 (95% CI: 0.999, 1.005)
and in HIGH was 0.89 (95% CI: 0.890, 0.896); for males
in LOW the rate was 1.01 (95% CI: 1.007, 1.012) and
in HIGH was 0.91.(95%CI: 0.912, 0.917; p < .0001).
Mean compliance rates were lower in the high share
group in every age category. The largest difference
occurred for participants 19yrs and younger, where
HIGH had a mean compliance rate of 0.98 (95% CI:
0.95, 1.02), and LOW 1.25 (95% CI: 1.21, 1.28; 
p < .0001). CONCLUSION: This study shows that high
participant cost sharing is associated with decreased 
medication compliance rates for a diabetic population.
While the goal of cost-sharing is to decrease total drug
spending, the amount saved may not offset the effects 
of decreased compliance for maintenance medications in
a diabetic population. More study is needed to better
understand compliance and cost-sharing.
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OBJECTIVES: Until 1995 sulfonylureas were the only
oral diabetes medications available in the United States.
Currently, there are expanded options in diabetes therapy
with ﬁve classes of oral medications. Our objective is to
test whether the newer therapies diffuse more quickly in
higher income areas among an insured population.
METHODS: All prescriptions for oral diabetes medica-
tion issued to patients in metropolitan Baltimore between
1999 and 2001 were selected from CareFirst Inc.’s claims
database. Records were aggregated to the patient level
with indicators for all classes of drugs used. Patients were
divided into those receiving only sulfonylureas and those
receiving at least one of the newer medications. Each
record was linked to census data for median income by
zip code. Linear and logistic regressions were performed
on microdata and data aggregated by zip code. Our null
hypothesis is that income is not associated with use of
newer therapies. We interpret a statistically signiﬁcant
coefﬁcient on income as evidence to reject the null.
RESULTS: The mean proportion of the population
receiving sulfonylureas only declined from 41% to 28%
over the three years. Regression results show a statisti-
cally signiﬁcant negative association between income and
monotherapy. Each $10,000 of income is associated with
a 1% increase in the share of the population recei-
ving newer medications. Controls for age and gender
strengthen this association. Between 1999 and 2001 
the coefﬁcient associating income and likelihood of
monotherapy increased from .003 to .011 (per $10,000).
CONCLUSIONS: Within an insured population, diabet-
ics residing in higher income neighborhoods are more
likely to receive one of the new drug therapies. The level
of this disparity increased over the course of our study. A
subsequent paper will distinguish between co-pay effects
and physician practice effects.
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OBJECTIVES: Maintaining glycemic control is one key
strategy to prevent diabetes-related complications. It is,
however, unclear whether non-adherence to oral antihy-
perglycemic medications contributes to the risk of com-
plications or other outcomes, such as hospitalization. Our
study examines the association between oral medication
non-adherence and subsequent hospitalization among
persons with Type 2 diabetes. METHODS: Administra-
tive claims data (2000 and 2001) from a managed care
organization in the midwestern U.S. were analyzed. The
study included 1270 enrollees, aged 18 and over, with
diabetes who were taking oral antihyperglycemic agents
both years but who did not use insulin. Non-adherence
was deﬁned as a medication possession ratio (MPR)
below 80%. To account for unobserved factors, condi-
tional multivariate logistic regression analyses were 
performed where hospitalization in 2001 was regressed
on non-adherence in 2000, while controlling for prior
hospitalization in 2000, age, gender, and multi-vs.-mono
oral therapy. An interaction term of adherence conver-
sions (from adherent to non-adherent, and vice versa)
between 2000 and 2001 was also analyzed. RESULTS:
Enrollees who were non-adherent to oral antihyper-
glycemic medications in 2000 had greater odds of being
hospitalized in 2001 (OR: 1.80; CI: 1.22–2.67) as com-
pared to those adherent in 2000. Although MPRs within
